Natera, Inc. (NASDAQ:NTRA) Insider Sells $149,837.04 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 1,026 shares of the business’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $146.04, for a total transaction of $149,837.04. Following the completion of the sale, the insider now owns 144,782 shares in the company, valued at $21,143,963.28. This represents a 0.70 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Solomon Moshkevich also recently made the following trade(s):

• On Wednesday, March 5th, Solomon Moshkevich sold 6,000 shares of Natera stock. The stock was sold at an average price of $143.29, for a total transaction of $859,740.00.
• On Wednesday, January 29th, Solomon Moshkevich sold 5,201 shares of Natera stock. The stock was sold at an average price of $165.87, for a total transaction of $862,689.87.
• On Wednesday, January 22nd, Solomon Moshkevich sold 24,861 shares of Natera stock. The stock was sold at an average price of $164.97, for a total transaction of $4,101,319.17.

Natera Stock Up 3.1 %

Shares of NASDAQ NTRA traded up $4.59 during trading hours on Wednesday, hitting $150.87. 2,162,925 shares of the stock were exchanged, compared to its average volume of 1,349,026. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The company has a market cap of $20.40 billion, a PE ratio of -85.72 and a beta of 1.80. The firm has a fifty day moving average price of $162.25 and a 200-day moving average price of $149.27. Natera, Inc. has a 12 month low of $83.13 and a 12 month high of $183.00.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.01. The firm had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. On average, sell-side analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on NTRA shares. Guggenheim lifted their price target on shares of Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a research note on Friday, January 17th. Morgan Stanley lifted their price objective on shares of Natera from $176.00 to $185.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. The Goldman Sachs Group lifted their price objective on shares of Natera from $160.00 to $190.00 and gave the company a “buy” rating in a report on Tuesday, January 28th. Canaccord Genuity Group reiterated a “buy” rating and set a $180.00 price objective on shares of Natera in a report on Wednesday, February 26th. Finally, Robert W. Baird lifted their price objective on shares of Natera from $183.00 to $188.00 and gave the company an “outperform” rating in a report on Friday, February 28th. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and a consensus price target of $178.12.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. LRI Investments LLC bought a new position in shares of Natera during the 4th quarter worth approximately $29,000. Blue Trust Inc. grew its position in Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after purchasing an additional 97 shares during the last quarter. Versant Capital Management Inc grew its position in Natera by 345.8% during the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after purchasing an additional 166 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in Natera by 372.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock worth $52,000 after purchasing an additional 261 shares during the last quarter. Finally, Principal Securities Inc. grew its position in Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after purchasing an additional 59 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.